LPPR2/PLPPR2 (Phospholipid Phosphatase Related Protein 2) Drug Discovery Landscape & Assay Solutions
- By admin
- 19 Aug 2026
- Comments
Target Identity: LPPR2 (also known as PLPPR2, PRG-3, PAP2d) — the primary UniProt entry is Q96GM1 (PLPPR2). The requested target LPPR2/PLPPR2 resolves to PLPPR2, a multi-pass transmembrane protein involved in neuronal membrane lipid metabolism.
Target Overview & Key Mutation
LPPR2 belongs to the phosphatidic acid phosphatase (PAP) family with a predicted 6-transmembrane domain topology. It regulates phosphatidic acid and lysophosphatidic acid signaling, critical for axon guidance, synaptic plasticity, and neuroinflammation.
Key Somatic Mutation (from UniProt VAR_038546): A somatic mutation identified in a colorectal cancer sample has been reported. This mutation may affect protein function or stability and should be considered in therapeutic strategies targeting LPPR2 in oncology contexts.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LPPR2/PLPPR2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LPPR2/PLPPR2 Full-Length Membrane Protein (HEK293 expressed, native glycosylation, detergent-solubilized or Nanodisc-embedded). Sequence verified. | View LPPR2 Products |
| Gene Delivery | LPPR2/PLPPR2 Lentivirus Premade Particles (≥10⁸ TU/mL, puromycin selection). For stable cell line construction in neuronal cells. | View LPPR2 Products |
| Benchmark Ab | Anti-LPPR2 (Recombinant rabbit mAb) for expression validation and immunoprecipitation. | View LPPR2 Products |
| Validator | LPPR2/PLPPR2 siRNA Set (3 unique targets) for knockdown verification and specificity controls. | View LPPR2 Products |
| Related Target: LPPR1 | LPPR1/PRG1 — Family member with overlapping CNS expression; critical for counter-screening. | View LPPR1 Products |
| Related Target: LPPR4 | LPPR4/PRG4 — Plasticity-related gene; assess subfamily redundancy in functional assays. | View LPPR4 Products |
| Related Target: LPPR5 | LPPR5 — Regulator of lipid phosphate metabolism; potential compensatory pathway partner. | View LPPR5 Products |
| Related Target: ENPP2 | ENPP2 (Autotaxin) — Synergistic lipid signaling pathway node. | View ENPP2 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass Membrane Topology (6 TMDs) | Lentivirus for Stable Cell Line: Preserves native conformation in neuronal membranes; HEK293T expression with neuronal promoters available |
| Complex Membrane Conformation | Lentivirus Premade Particles for stable cell line construction ensuring correct membrane insertion |
| Lipid Phosphatase Activity Measurement | Full-length Protein Access: Sequence-verified construct with intact catalytic domains for PIPase activity assays |
| Subfamily Selectivity (LPPR vs PPAP2) | Ortholog Panel: Human, Mouse, Rat LPPR2 proteins with >95% purity for cross-species pharmacology; also includes LPPR1/4/5 for counter-screening |
| Lack of Controls / False Positives | Clinical Benchmark Antibodies included; Validated siRNA set for specificity checks |
| Neuronal Specificity Validation | Validated siRNA Controls: Triple-target set for specific knockdown verification in SH-SY5Y or primary neurons |
| Endotoxin Sensitivity in CNS Models | Endotoxin Controlled: <1 EU/μg specification for primary neuronal culture compatibility |
Live LPPR2/PLPPR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Plasticity Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
LPPR2 represents an emerging target in neuronal membrane lipid metabolism. Unlike traditional kinase-centric CNS targets, the LPPR family regulates phosphatidic acid and lysophosphatidic acid signaling—lipid second messengers critical for axon guidance, synaptic plasticity, and neuroinflammation. The current therapeutic landscape for LPPR2 remains predominantly in preclinical discovery, with academic interest focused on traumatic CNS injury, neuropathic pain, and neurodegenerative conditions. As the field recognizes the limitations of traditional GPCR and kinase targets for CNS indications, lipid phosphatases like LPPR2 are gaining attention for their ability to modulate membrane dynamics and growth cone behavior.
The race for LPPR2 therapeutics is intensifying, with major players shifting focus from traditional GPCR modulators to enzymatic regulators of lipid signaling. As first-generation small molecule inhibitors enter lead optimization, the next wave of R&D is targeting allosteric modulators and biologics capable of crossing the blood-brain barrier while avoiding systemic lipid metabolism disruption. The somatic mutation found in colorectal cancer also hints at a potential role in oncology, expanding the therapeutic scope beyond neurology.
Molecular Architecture & Assay Implications
LPPR2 is a multi-pass transmembrane protein (predicted 6 TMDs) belonging to the phosphatidic acid phosphatase (PAP) family. Critical structural considerations for assay development include:
- Catalytic Site Accessibility: The active site faces the extracellular/luminal space, requiring intact membrane insertion for activity assays.
- Glycosylation State: Native glycosylation (HEK293 expression) essential for proper trafficking and antibody epitope recognition.
- Lipid Environment Dependence: Activity requires specific phospholipid membrane composition—cell-based assays superior to biochemical assays.
- Orthosteric vs Allosteric Sites: The catalytic pocket is highly conserved; allosteric modulation (possibly in transmembrane or extracellular loops) may offer better subtype selectivity.
Competitive Modality & Indication Snapshot
| Modality | Development Stage | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|---|
| Small Molecule Inhibitors | Lead Optimization | Academic/Biotech Consortiums | Neurological Disorders (TBI, Stroke) | Catalytic Activity Assay (Need full-length membrane protein in native lipid environment) |
| Allosteric Modulators | Target Validation | Early-stage Biotech | Neuropathic Pain | Conformational Shift Detection (Need stable cell lines expressing WT vs mutant receptors) |
| Antibody-Based (Fabs) | Early Discovery | Small Biotechs | Neuroinflammation | Internalization Assay (Need high-purity ECD with correct glycosylation) |
| Gene Therapy (AAV) | Preclinical | Preclinical Institutes | Spinal Cord Injury, Axon Regeneration | Expression Validation (Need specific antibodies for tissue penetration analysis; lentivirus for overexpression) |
| Monoclonal Antibody | Early-stage | Early-stage Biotech | Oncology / Metabolic | Epitope Validation (Need Sequence Verified antigens) |